125 related articles for article (PubMed ID: 37043921)
1. Cadmium exposure and the risk of prostate cancer among Nigerian men: Effect modification by zinc status.
Bede-Ojimadu O; Nnamah N; Onuegbu J; Grant-Weaver I; Barraza F; Orakwe J; Abiahu J; Orisakwe OE; Nriagu J
J Trace Elem Med Biol; 2023 Jul; 78():127168. PubMed ID: 37043921
[TBL] [Abstract][Full Text] [Related]
2. Oxidative damage in patients with benign prostatic hyperplasia and prostate cancer co-exposed to phthalates and to trace elements.
Chang WH; Lee CC; Yen YH; Chen HL
Environ Int; 2018 Dec; 121(Pt 2):1179-1184. PubMed ID: 30808488
[TBL] [Abstract][Full Text] [Related]
3. Zinc and cadmium concentrations in indigenous blacks with normal, hypertrophic, and malignant prostate.
Ogunlewe JO; Osegbe DN
Cancer; 1989 Apr; 63(7):1388-92. PubMed ID: 2465818
[TBL] [Abstract][Full Text] [Related]
4. Zinc and cadmium analysis in human prostate neoplasms.
Bryś M; Nawrocka AD; Miekoś E; Zydek C; Foksiński M; Barecki A; Krajewska WM
Biol Trace Elem Res; 1997; 59(1-3):145-52. PubMed ID: 9522056
[TBL] [Abstract][Full Text] [Related]
5. Trace elements and vitamin E status in Nigerian patients with prostate cancer.
Adaramoye OA; Akinloye O; Olatunji IK
Afr Health Sci; 2010 Mar; 10(1):2-8. PubMed ID: 20811517
[TBL] [Abstract][Full Text] [Related]
6. Environmental exposure to trace elements and prostate cancer in three New Zealand ethnic groups.
Gray MA; Centeno JA; Slaney DP; Ejnik JW; Todorov T; Nacey JN
Int J Environ Res Public Health; 2005 Dec; 2(3-4):374-84. PubMed ID: 16819092
[TBL] [Abstract][Full Text] [Related]
7. The Prevalence of Zinc Deficiency among Men with and without Prostate Cancer in Port Harcourt, Nigeria.
Amadi C; Aleme BM
Nutr Cancer; 2020; 72(6):1018-1025. PubMed ID: 31522560
[No Abstract] [Full Text] [Related]
8. Concentration of trace elements in blood of Polish patients with prostate cancer.
Drozdz-Afelt JM; Koim-Puchowska B; Kaminski P
Environ Toxicol Pharmacol; 2024 Apr; 107():104425. PubMed ID: 38552756
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of lipids, total antioxidants, and trace metals in benign prostate hyperplasia and prostate cancer.
Adedapo KS; Arinola OG; Shittu OB; Kareem OI; Okolo CA; Nwobi LN
Niger J Clin Pract; 2012; 15(3):293-7. PubMed ID: 22960963
[TBL] [Abstract][Full Text] [Related]
10. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men.
Ørsted DD; Bojesen SE; Nielsen SF; Nordestgaard BG
Eur Urol; 2011 Oct; 60(4):691-8. PubMed ID: 21705134
[TBL] [Abstract][Full Text] [Related]
11. Prediagnostic toenail cadmium and zinc and subsequent prostate cancer risk.
Platz EA; Helzlsouer KJ; Hoffman SC; Morris JS; Baskett CK; Comstock GW
Prostate; 2002 Sep; 52(4):288-96. PubMed ID: 12210489
[TBL] [Abstract][Full Text] [Related]
12. Zinc and cadmium in cell fractions of prostatic cancer tissues of different histological grading in comparison to BPH and normal prostate.
Feustel A; Wennrich R
Urol Res; 1984; 12(2):147-50. PubMed ID: 6204433
[TBL] [Abstract][Full Text] [Related]
13. Exposure to heavy metal elements may significantly increase serum prostate-specific antigen levels with overdosed dietary zinc.
Fang Y; Chen C; Chen X; Song J; Feng S; Li Z; Li Z; Xiong Y; Zhang Q; Su H; Liu H; Zhu G; Hu B; Wang W; Liu Z; Jiao K; Zhang C; Zhang F; Jiang K; He J; Sun Z; Yuan D; Chen W; Zhu J
Ecotoxicol Environ Saf; 2024 Mar; 272():116080. PubMed ID: 38350215
[TBL] [Abstract][Full Text] [Related]
14. BPH: a tell-tale sign of prostate cancer? Results from the Prostate Cancer and Environment Study (PROtEuS).
Boehm K; Valdivieso R; Meskawi M; Larcher A; Sun M; Sosa J; Blanc-Lapierre A; Weiss D; Graefen M; Saad F; Parent MÉ; Karakiewicz PI
World J Urol; 2015 Dec; 33(12):2063-9. PubMed ID: 25824539
[TBL] [Abstract][Full Text] [Related]
15. Circadian characteristics of serum calcium, magnesium and eight trace elements and of their metallo-moieties in urine of healthy middle-aged men.
Kanabrocki EL; Sothern RB; Ryan MD; Kahn S; Augustine G; Johnson C; Foley S; Gathing A; Eastman G; Friedman N; Nemchausky BA; Kaplan E
Clin Ter; 2008; 159(5):329-46. PubMed ID: 18998036
[TBL] [Abstract][Full Text] [Related]
16. CCR2 and CCR5 genes polymorphisms in benign prostatic hyperplasia and prostate cancer.
Zambra FM; Biolchi V; Brum IS; Chies JA
Hum Immunol; 2013 Aug; 74(8):1003-8. PubMed ID: 23632061
[TBL] [Abstract][Full Text] [Related]
17. [Health risk assessment of exposure to metals in the workers of the steel foundry and in the general population of Taranto (Italy)].
Soleo L; Lovreglio P; Panuzzo L; D'Errico MN; Basso A; Gilberti ME; Drago I; Tomasi C; Apostoli P
G Ital Med Lav Ergon; 2012; 34(4):381-91. PubMed ID: 23477104
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen levels in relation to cadmium exposure and zinc intake: results from the 2001-2002 National Health and Nutrition Examination Survey.
van Wijngaarden E; Singer EA; Palapattu GS
Prostate; 2008 Feb; 68(2):122-8. PubMed ID: 18044729
[TBL] [Abstract][Full Text] [Related]
19. Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism.
Wang L; Habuchi T; Mitsumori K; Li Z; Kamoto T; Kinoshita H; Tsuchiya N; Sato K; Ohyama C; Nakamura A; Ogawa O; Kato T
Int J Cancer; 2003 Jan; 103(1):116-20. PubMed ID: 12455063
[TBL] [Abstract][Full Text] [Related]
20. Metformin use and prostate cancer risk.
Preston MA; Riis AH; Ehrenstein V; Breau RH; Batista JL; Olumi AF; Mucci LA; Adami HO; Sørensen HT
Eur Urol; 2014 Dec; 66(6):1012-20. PubMed ID: 24857538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
